The effects of sirolimus on urothelial lesions chemically induced in ICR mice by BBN

Anticancer Research

Volumn 29, Issue 8, 2009, Pages 3221-3226

  Oliveira, Paula A ^a   Arantes Rodrigues, Regina ^a   Sousa Diniz, Clarisse ^a   Colaço, Aura ^a   Lourenço, Lígia ^a   De La Cruz P, Luis Felipe ^b   Da Silva, Vítor Moreira ^c   Afonso, Julieta ^d   Lopes, Carlos ^e   Santos, Lucio ^c,f  

^a UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^d Alto Ave Superior Institute of Health ^*  (United States)

^e UNIVERSITY OF PORTO   (Portugal)

^f UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

BBN; Labelling index; Mice; Sirolimus; Urothelial lesions

Indexed keywords

DRINKING WATER; KI 67 ANTIGEN; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BLADDER CANCER; CONTROLLED STUDY; DRUG EFFECT; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INSTITUTE FOR CANCER RESEARCH MOUSE; LABELING INDEX; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; UROGENITAL TRACT CANCER; UROGENITAL TRACT TUMOR;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BUTYLHYDROXYBUTYLNITROSAMINE; CARCINOMA IN SITU; CARCINOMA, PAPILLARY; HYPERPLASIA; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED ICR; SIROLIMUS; URINARY BLADDER NEOPLASMS;

EID: 68549090703     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Franekova M, Halasova E, Bukovska E, Luptak J and Dobrota D: Gene polymorphisms in bladder cancer. Urol Oncol 26: 1-8, 2007.
2. Stein JP and Skinner DG: Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol 3: 296-304, 2006. (Pubitemid 44143761)
3. Oliveira PA, Colaco A, De la Cruz P LF and Lopes C: Experimental bladder carcinogenesis - rodent models. Exp Oncol 28: 2-11, 2006.
4. Wan X and Helman LJ: The biology behind mTOR inhibition in sarcoma. Oncologist 12: 1007-1018, 2007.
5. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK and Sawyers CL: Antitumor activity of rapamycin in a phase I trial for patients with recurrent pten-deficient glioblastoma. PLoS Med 5: 139-155, 2008. (Pubitemid 351198268)
6. Cejka D, Preusser M, Fuereder T, Sieghart W, Werzowa J, Strommer S and Wacheck V: mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo. Anticancer Res 28: 3801-3808, 2008.
7. Huang S and Houghtoun PJ: Inhibitors of mammalian target of rapamycin as a novel agents: from bench to clinic. Curr Opinion Invest Drugs 3: 295-304, 2002. (Pubitemid 34456089)
8. Dutcher JP: Mammalian target of rapamycin inhibition. Clin Cancer Res 10: 6382S-6387S, 2004.
9. Hidalgo M and Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19: 6680-6686, 2000. (Pubitemid 32197708)
10. Dudkin L, Dilling MB, Cheshire PJ, Harwood FC, Hollingshead M, Arbuck SG, Travis R, Sausville EA and Houghton PJ: Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 7: 1758-1764, 2001.
11. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C and Blenis J: mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24: 200-216, 2004. (Pubitemid 38010048)
12. Kasukabe T, Okabe-Kado J, Kato N, Sassa T and Honma Y: Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation- inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Res 7: 1097-1110, 2005.
13. Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW and Griffin G: Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 5: 2676-2684, 2006. (Pubitemid 44848994)
14. Mosley JD, Poirier JT, Seachrist DD, Landis MD and Keri RA: Rapamycin inhibits multiple stages of c-Neu/ErbB2-induced tumor progression in a transgenic mouse model of HER2-positive breast cancer. Mol Cancer Ther 6: 2188-2197, 2007.
15. Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley H.H, Schilder RJ, Ozols RF and Testa JR: RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 13: 4261-4270, 2007.
16. Dowling RJ, Zakikhani M, Fantus IG, Pollak M and Sonenberg N: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67: 10804-10812, 2007. (Pubitemid 350145909)
17. Kenerson H, Dundon TA and Yeung RS: Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res 57: 67-75, 2005. (Pubitemid 40039895)
18. Khariwala SS, Kjaergaard J, Lorenz R, Van Lente F, Shu S and Strome M: Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII). Laryngoscope 116: 814-820, 2006.
19. Legrier ME, Yang CP, Yan HG, Lopez-Barcons L, Keller S, Pérez-Soler R, Horwitz SB and McDaid HM: Targeting protein translation in human non-small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res 67: 11300-11308, 2007. (Pubitemid 350248556)
20. Wu Q, Kiguchi K, Kawamoto T, Ajiki T, Traag J, Carbajal S, Ruffino L, Thames H, Wistuba I, Thomas M, Vasquez KM and DiGiovanni J: Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Cancer Res 67: 3794-3800, 2007. (Pubitemid 46762166)
21. Huynh H, Teo CC and Soo KC: Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Mol Cancer Ther 6: 2959-12566, 2007. (Pubitemid 350206774)
22. Lang SA, Gaumann A, Koehl GE, Seidel U, Bataille F, Klein D, Ellis LM, Bolder U, Hofstaedter F, Schlitt HJ, Geissler EK and Stoeltzing O: Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 120: 1803-1810, 2007.
23. Pinto-Leite R, Botelho P, Ribeiro E, Oliveira PA and Santos L: Effect of sirolimus on urinary bladder cancer T24 cell line. J Exp Clin Cancer Res, 2009.
24. Oliveira P, Palmeira C, Colaço A, De la Cruz PLF and Lopes C: Cell proliferation and DNA content in rat urothelial lesions after repeat intravesical instillations of mitomycin C and bacillus Calmette-Guérin. Urol Int 80: 90-97, 2008.
25. Epstein JI, Amin MB, Reuter VR and Mostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22: 1435-1448, 1998.
26. Parada B, Figueiredo A, Reis F, Nunes P, Eufrásio P, Dinis H, Dias A, Teixeira EL, Teixeira F and Mota A: Effects of sirolimus on rat urinary bladder carcinogenesis. Eur Urol Suppl 7: 211, 2008.
27. Wang SM, Tai HC, Chueh SC, Chung SD and Lai MK: Sirolimus does not absolutely abolish the occurrence/recurrence of urothelial carcinoma in renal transplant recipients. Transplant Proc 40: 2395-2396, 2008.
28. Fechner G, Classen K, Schmidt D, Hauser S and Müller SC: Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer. Urology 73: 665-668, 2009.
29. Diao Y, Ma J, Xiao WD, Luo J, Li XY, Chu KW, Fung PW, Habib N, Farzaneh F and Xu RA: Inhibition of angiogenesis and HCT-116 xenograft tumor growth in mice by kallistatin. World J Gastroenterol 13: 4615-4619, 2007. (Pubitemid 47455244)
30. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, Shen MM, Cordon-Cardo C and Abate-Shen C: Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 23: 655-659, 2009.